CCA
CLVS

Conservest Capital Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Conservest Capital Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,316
Closed -$206K – 81
2019
Q1 		$206K Sell
8,316
-10,116
-55% -$254K 0.03% 78
2018
Q4 		$331K Hold
18,432
– – 0.05% 62
2018
Q3 		$541K Hold
18,432
– – 0.08% 53
2018
Q2 		$838K Buy
18,432
+6,552
+55% +$319K 0.13% 46
2018
Q1 		$627K Hold
11,880
– – 0.14% 41
2017
Q4 		$808K Hold
11,880
– – 0.16% 39
2017
Q3 		$979K Buy
11,880
+8,183
+221% +$649K 0.16% 48
2017
Q2 		$346K Hold
3,697
– – 0.07% 57
2017
Q1 		$235K Buy
+3,697
New +$225K 0.05% 74

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Conservest Capital Advisors's CLVS Position: Q2 2019 in Review

Conservest Capital Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 8,316 shares — an estimated $206K sold.

Conservest Capital Advisors first reported a position in CLVS in Q1 2017 and held it in 9 quarters. The position peaked at $979K in Q3 2017. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Conservest Capital Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Conservest Capital Advisors sold 8,316 Clovis Oncology, Inc. shares in Q2 2019, an estimated $206K.
  • Conservest Capital Advisors first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 9 quarters.
  • Conservest Capital Advisors's Clovis Oncology, Inc. position peaked at $979K in Q3 2017.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Conservest Capital Advisors's 13F filing for Q2 2019, filed 10 Jul 2019.